Publications of Pavel Sinitcyn
All genres
Journal Article (12)
1.
Journal Article
41, pp. 1776 - 1786 (2023)
Global detection of human variants and isoforms by deep proteome sequencing. Nature Biotechnology 2.
Journal Article
14 (1), 5252 (2023)
Deep and fast label-free Dynamic Organellar Mapping. Nature Communications 3.
Journal Article
12, e75191 (2023)
Multi-targeted therapy resistance via drug-induced secretome fucosylation. eLife 4.
Journal Article
40 (4), pp. 463 - 481 (2022)
Progress and challenges in mass spectrometry-based analysis of antibody repertoires. Trends in Biotechnology 5.
Journal Article
39, pp. 1563 - 1573 (2021)
MaxDIA enables library-based and library-free data-independent acquisition proteomics. Nature Biotechnology 6.
Journal Article
1 (1), pp. 207 - 234 (2018)
Computational Methods for Understanding Mass Spectrometry-Based Shotgun Proteomics Data. Annual Review of Biomedical Data Science 7.
Journal Article
7, e37018 (2018)
The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins. eLife 8.
Journal Article
15 (6), p. 401 - 401 (2018)
MaxQuant goes Linux. Nature methods 9.
Journal Article
7, 13404 (2016)
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nature Communications 10.
Journal Article
8, 44 (2016)
Ultra-deep and quantitative saliva proteome reveals dynamics of the oral microbiome. GENOME MEDICINE 11.
Journal Article
13 (9), pp. 731 - 740 (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data. Nature methods 12.
Journal Article
15 (8), pp. 1453 - 1456 (2015)
Visualization of LC-MS/MS proteomics data in MaxQuant. PROTEOMICS Meeting Abstract (1)
13.
Meeting Abstract
41 (Suppl. 4), pp. 85 - 86. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Wien, September 28, 2018 - October 02, 2018. Karger, Basel (2018)
Spatial and temporal monitoring of neoantigen-specific T cells and T-cell receptors in a melanoma patient with secondary immune resistance to Ipilimumab. In Oncology Research and Treatment,